evaluated data from over 6,000 patients with breast cancer, explored across 10 publicly available studies, and reported that around 20% of PIK3CA mutations would not have been detected by the therascreen PCR-based companion test (28). The gene discussed is PIK3CA; the disease is breast carcinoma.